$7.085
Insights on Orasure Technologies Inc
Revenue is up for the last 2 quarters, 85.44M → 89.18M (in $), with an average increase of 4.2% per quarter
Netprofit is up for the last 2 quarters, -4.79M → 11.15M (in $), with an average increase of 143.0% per quarter
In the last 1 year, West Pharmaceutical Services Inc has given 45.4% return, outperforming this stock by 3.1%
In the last 3 years, West Pharmaceutical Services Inc has given 27.9% return, outperforming this stock by 72.3%
0.28%
Downside
Day's Volatility :4.59%
Upside
4.32%
38.22%
Downside
52 Weeks Volatility :43.99%
Upside
9.34%
Period | Orasure Technologies Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.83% | 0.0% | 0.0% |
6 Months | 28.82% | 2.2% | 0.0% |
1 Year | 42.27% | -4.7% | -2.1% |
3 Years | -44.43% | 18.0% | -6.5% |
Market Capitalization | 526.1M |
Book Value | $5.51 |
Dividend Share | 0.0 |
Dividend Yield | 0.74% |
Earnings Per Share (EPS) | 0.65 |
PE Ratio | 11.02 |
PEG Ratio | 2.3 |
Wall Street Target Price | 6.0 |
Profit Margin | 10.73% |
Operating Margin TTM | 19.1% |
Return On Assets TTM | 7.0% |
Return On Equity TTM | 13.01% |
Revenue TTM | 452.7M |
Revenue Per Share TTM | 6.19 |
Quarterly Revenue Growth YOY | -23.400000000000002% |
Gross Profit TTM | 147.6M |
EBITDA | 71.1M |
Diluted Eps TTM | 0.65 |
Quarterly Earnings Growth YOY | 0.95 |
EPS Estimate Current Year | 0.54 |
EPS Estimate Next Year | -0.24 |
EPS Estimate Current Quarter | 0.04 |
EPS Estimate Next Quarter | 0.03 |
What analysts predicted
Downside of 15.31%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 167.1M | ↑ 30.32% |
Net Income | 30.9M | ↑ 56.94% |
Net Profit Margin | 18.52% | ↑ 3.14% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 181.7M | ↑ 8.79% |
Net Income | 20.4M | ↓ 34.1% |
Net Profit Margin | 11.22% | ↓ 7.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 154.6M | ↓ 14.93% |
Net Income | 16.7M | ↓ 18.34% |
Net Profit Margin | 10.77% | ↓ 0.45% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 171.7M | ↑ 11.07% |
Net Income | -14.9M | ↓ 189.59% |
Net Profit Margin | -8.69% | ↓ 19.46% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 233.7M | ↑ 36.08% |
Net Income | -23.0M | ↑ 54.12% |
Net Profit Margin | -9.84% | ↓ 1.15% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 387.5M | ↑ 65.82% |
Net Income | -17.9M | ↓ 22.01% |
Net Profit Margin | -4.63% | ↑ 5.21% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 80.2M | ↑ 18.5% |
Net Income | -18.8M | ↓ 5.83% |
Net Profit Margin | -23.43% | ↑ 6.06% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 116.5M | ↑ 45.16% |
Net Income | 5.3M | ↓ 128.04% |
Net Profit Margin | 4.53% | ↑ 27.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 123.1M | ↑ 5.68% |
Net Income | 15.6M | ↑ 195.11% |
Net Profit Margin | 12.64% | ↑ 8.11% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 155.0M | ↑ 25.91% |
Net Income | 27.2M | ↑ 74.92% |
Net Profit Margin | 17.56% | ↑ 4.92% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 85.4M | ↓ 44.86% |
Net Income | -4.8M | ↓ 117.62% |
Net Profit Margin | -5.61% | ↓ 23.17% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 89.2M | ↑ 4.38% |
Net Income | 11.2M | ↓ 332.67% |
Net Profit Margin | 12.51% | ↑ 18.12% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 296.2M | ↑ 42.45% |
Total Liabilities | 38.1M | ↑ 72.61% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 315.6M | ↑ 6.54% |
Total Liabilities | 32.2M | ↓ 15.55% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 349.3M | ↑ 10.69% |
Total Liabilities | 42.2M | ↑ 30.93% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 454.5M | ↑ 30.11% |
Total Liabilities | 55.9M | ↑ 32.62% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 461.0M | ↑ 1.43% |
Total Liabilities | 80.5M | ↑ 43.93% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 444.7M | ↓ 3.53% |
Total Liabilities | 81.1M | ↑ 0.78% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 429.3M | ↓ 1.44% |
Total Liabilities | 85.1M | ↑ 20.41% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 432.2M | ↑ 0.69% |
Total Liabilities | 90.3M | ↑ 6.18% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 444.7M | ↑ 2.89% |
Total Liabilities | 81.1M | ↓ 10.22% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 459.4M | ↑ 3.31% |
Total Liabilities | 65.2M | ↓ 19.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 453.6M | ↓ 1.27% |
Total Liabilities | 59.5M | ↓ 8.86% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 458.4M | ↑ 1.07% |
Total Liabilities | 16.8M | ↓ 71.76% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 28.2M | ↑ 23.67% |
Investing Cash Flow | -96.4M | ↑ 1094.71% |
Financing Cash Flow | 30.4M | ↓ 2735.06% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 39.1M | ↑ 38.83% |
Investing Cash Flow | -17.4M | ↓ 81.91% |
Financing Cash Flow | -1.9M | ↓ 106.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.8M | ↓ 74.92% |
Investing Cash Flow | -19.8M | ↑ 13.6% |
Financing Cash Flow | -4.7M | ↑ 147.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.8M | ↓ 40.77% |
Investing Cash Flow | -14.0M | ↓ 29.14% |
Financing Cash Flow | 92.5M | ↓ 2075.2% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -35.4M | ↓ 709.3% |
Investing Cash Flow | -5.5M | ↓ 60.79% |
Financing Cash Flow | -2.8M | ↓ 103.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.2M | ↑ 33.41% |
Investing Cash Flow | 21.1M | ↓ 483.29% |
Financing Cash Flow | -3.8M | ↑ 35.89% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.7M | ↓ 73.01% |
Investing Cash Flow | 7.7M | ↓ 177.22% |
Financing Cash Flow | -1.1M | ↓ 17.99% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 16.3M | ↓ 268.59% |
Investing Cash Flow | -2.2M | ↓ 128.98% |
Financing Cash Flow | -488.0K | ↓ 57.34% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.0M | ↓ 210.51% |
Investing Cash Flow | 25.6M | ↓ 1249.87% |
Financing Cash Flow | -801.0K | ↑ 64.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.0M | ↓ 133.32% |
Investing Cash Flow | 1.0M | ↓ 96.03% |
Financing Cash Flow | -1.3M | ↑ 66.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 57.3M | ↑ 854.15% |
Investing Cash Flow | 37.2M | ↑ 3556.99% |
Financing Cash Flow | -632.0K | ↓ 52.52% |
Sell
Neutral
Buy
Orasure Technologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Orasure Technologies Inc | 23.22% | 28.82% | 42.27% | -44.43% | -42.3% |
![]() Intuitive Surgical, Inc. | 11.33% | 0.98% | 15.79% | 21.77% | 89.3% |
![]() Resmed Inc. | 9.14% | -23.64% | -26.19% | -21.61% | 49.1% |
![]() Becton, Dickinson And Company | -8.85% | -7.45% | -5.29% | -1.27% | -0.42% |
![]() West Pharmaceutical Services Inc | 3.79% | -0.52% | 45.38% | 27.93% | 223.46% |
![]() Alcon Ag | -2.36% | -7.37% | 5.98% | 12.67% | 23.93% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Orasure Technologies Inc | 11.02 | 11.02 | 2.3 | 0.54 | 0.13 | 0.07 | 0.01 | 5.51 |
![]() Intuitive Surgical, Inc. | 73.99 | 73.99 | 4.48 | 5.59 | 0.13 | 0.08 | 0.0 | 35.62 |
![]() Resmed Inc. | 26.27 | 26.27 | 2.04 | 6.52 | 0.24 | 0.12 | 0.01 | 28.9 |
![]() Becton, Dickinson And Company | 46.72 | 46.72 | 1.28 | 12.22 | 0.06 | 0.03 | 0.02 | 88.83 |
![]() West Pharmaceutical Services Inc | 47.61 | 47.61 | 4.06 | 7.99 | 0.21 | 0.13 | 0.0 | 38.76 |
![]() Alcon Ag | 80.47 | 80.47 | 2.05 | 2.72 | 0.02 | 0.02 | 0.0 | 40.86 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Orasure Technologies Inc | Buy | $526.1M | -42.3% | 11.02 | 10.73% |
![]() Intuitive Surgical, Inc. | Buy | $111.0B | 89.3% | 73.99 | 22.14% |
![]() Resmed Inc. | Buy | $23.8B | 49.1% | 26.27 | 20.72% |
![]() Becton, Dickinson And Company | Buy | $69.2B | -0.42% | 46.72 | 7.66% |
![]() West Pharmaceutical Services Inc | Buy | $26.1B | 223.46% | 47.61 | 19.12% |
![]() Alcon Ag | Buy | $36.0B | 23.93% | 80.47 | 4.85% |
BlackRock Inc
Vanguard Group Inc
Camber Capital Management LLC
Dimensional Fund Advisors, Inc.
Neuberger Berman Group LLC
State Street Corporation
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
Organization | Orasure Technologies Inc |
Employees | 840 |
CEO | Mr. Scott Gleason |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$7.09
-3.87%
Advisorshares Alpha Dna Equity Sentiment Etf
$7.09
-3.87%
Falcon's Beyond Global Inc
$7.09
-3.87%
Jaguar Global Growth Corporation I
$7.09
-3.87%
Missfresh Ltd
$7.09
-3.87%
Shuaa Partners Acquisition Corp I
$7.09
-3.87%
Rose Hill Acquisition Corp
$7.09
-3.87%
Partners Bancorp
$7.09
-3.87%
Mercantile Bank Corp
$7.09
-3.87%